Pharmaceutical industry – Page 11
-
BusinessModerna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
ArticleThe future is bright: protecting innovation during uncertain times
The annual Pharma Integrates event facilitates conversation and collaboration to drive future innovation and improve patient outcomes worldwide
-
OpinionThe ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted
-
OpinionA promising peep at Covid-19 vaccine efficacy
Pfizer–BioNTech’s will need to be one of many if we are to overcome the pandemic
-
BusinessEarly indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
-
BusinessInnovation is a fragile transition state
Brexit and Covid-19 will likely stifle interactions, but could also stimulate new ones
-
BusinessStepping towards diversity in industry
Companies are re-affirming their commitment to inclusivity, even as the US government obstructs education efforts
-
OpinionImproving executive diversity is a priority
A few hiring decisions could make a big difference at leadership level
-
PodcastSofosbuvir
The hepatitis C drug that made waves when first launched – quicker to work and with fewer side effects than existing drugs, but it came with a hefty price tag
-
BusinessEU commits to overhaul of chemicals legislation
The Chemicals Strategy for Sustainability promises the biggest reform since Reach
-
BusinessCovid-19 highlights need to update pharma supply chains
Resilience and redundancy are key amid protectionist calls for domestic manufacturing
-
OpinionBlood offering
Antibodies in various forms could bridge the Covid-19 treatment gap until a vaccine is available
-
OpinionJumping the vaccine queue
Deals between companies and rich governments offset manufacturing risks, but must not compromise supplies to those in need
-
BusinessCovid-19 vaccine deals risk skewing supply
International accords including Covax aiming to ensure equitable distribution to poorer countries
-
BusinessProtein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
-
BusinessRussian Covid-19 vaccine data raises questions
Suspected data manipulation or fabrication casts shadows over safety trial report for hastily-approved Sputnik V
-
BusinessDrop in plasma donations hits immunoglobulin supply
Lockdown and social distancing have discouraged donors, and the potential impact of convalescent plasma collection for Covid-19 treatment is unclear
-
ArticleExploring the advantages of single-crystal x-ray diffraction in pharma
Single-crystal x-ray diffraction (SCXRD) in drug development is evolving. Johnson Matthey outlines how technology advances and regulations are reshaping its role in pharma
-
OpinionFacing the challenge of vaccine trials
Russia’s Covid-19 gamble is a stark contrast to even accelerated clinical programmes
-
BusinessRussian vaccine launch shocks scientists
Sputnik V to be approved without large human trial data